BTIG Starts Talis Biomedical Corp. (TLIS) at Buy
- S&P 500, Dow climb for third day and close at records
- Tesla (TSLA) China Numbers 'Robust' - Wedbush
- Apple (AAPL) Shares Seen as 'Attractive' as Recent Checks Show Continuously Strong Demand - Citi
- Amazon.com warehouse workers vote to reject forming union in Alabama
BTIG analyst Mark Massaro initiates coverage on Talis Biomedical Corp. (NASDAQ: TLIS) with a Buy rating and a price target of $18.00.
Shares of Talis Biomedical Corp. closed at $12.85 yesterday.
You May Also Be Interested In
- UPDATE: Northland Capital Markets Starts Zovio Inc (ZVO) at Outperform; Sees 100%+ Upside
- UPDATE: Goldman Sachs Starts US Steel (X) at Neutral
- UPDATE: Berenberg Starts Pacira Pharmaceuticals (PCRX) at Buy